| | Study | Year | Study region | Study continent | Tumor type | Sample size | Follow-up time mean (months) | Patients average age (years) | Serum sample collected time | Stage | CA15-3 cut-off value (U/ml) | Outcome | CEA cut-off value (ng/ml) | Outcome | Whether had association of clinicopathological characteristics with CA15-3 or CEA | NOS score |
| | Albuquerque | 1995 | UK | Europe | Metastatic breast cancers | 85 | N | 60.52 | Pretreatment | M | 40 | OS | 4 | OS | No | 6 | | Berruti | 1994 | Italy | Europe | Advanced breast cancer | 115 | 35 | 56 | At first recurrence of disease before the start of any endocrine or cytotoxic therapy | M | 30 | OS | N | N | No | 5 | | Canizares | 2001 | Spain | Europe | Primary early breast cancer | 364 | 72 | 56 | Pretreatment | I, II, III | 40 | DFS, OS | 6 | DFS, OS | No | 7 | | Chen | 2015 | China | Asia | Breast cancer with positive lymph nodes | 220 | 36 | 49.0 | Pretreatment | II, III, IV | 28 | OS | N | N | No | 7 | | Dai | 2016 | China | Asia | Triple-negative breast cancer | 247 | 120 | 46.8 | Pretreatment | I–IV | 21.8 | DFS, OS | 6.0 | DFS, OS | Yes | 7 | | Darlix | 2016 | France | Europe | Metastatic breast cancers | 250 | 40.8 | 58.4 | Not pretreatment | M | 30 | OS | N | N | No | 6 | | Di Gioia | 2015 | Germany | Europe | Early-stage breast cancer | 241 | 41.5 | 57 | Pretreatment | I, II, III | 24 | DFS, CSS | N | N | Yes | 7 | | Duffy | 2004 | UK | Europe | Breast cancer | 600 | 75.24 | N | Pretreatment | Not clear | 30 | OS | N | N | Yes | 7 | | Elfagieh | 2012 | Libya | Africa | 29 had locoregional breast cancer and 21 advanced breast cancer | 50 | 28 | N | Not clear | I–IV | 35.57 | OS | 8.82 | OS | Yes | 6 | | Giovanella | 2002 | Italy | Europe | Primary breast cancer | 212 | 26 | 53.6 | Pretreatment | I–IV | 30 | OS | 5 | OS | No | 7 | | Hewala | 2013 | Egypt | Africa | Stages II and III breast cancer | 100 | 50 | 48.36 | Pretreatment | II, III | | N | 4.88 | DFS | No | 8 | | James | 2003 | UK | Europe | Bone metastasis breast cancer | 213 | N | N | After metastasis | M | 35 | OS | 10 | OS | No | 7 | | Kacan | 2016 | Turkey | Europe | Early-stage breast cancer | 448 | 50 | 51 | Pretreatment | I, II, III | 31.3 | DFS, OS | 5 | DFS, OS | No | 8 | | Kumpulainen | 2002 | Finland | Europe | Primary breast cancer | 272 | 124.8 | 54 | In most patients, CA15-3 was assessed pre-first treatment; in the minority, by 4 weeks after the operation | 0–IV | 30 | OS | N | N | Yes | 7 | | Lee | 2013 | Korea | Asia | Metastatic breast cancers | 349 | 18 | | At recurrence | M | 20.11 | OS | 3.88 | OS | Yes | 6 | | Loprinzi | 1986 | South Africa | Africa | Metastatic breast cancers | 97 | N | N | After recurrence | M | N | N | 5 | OS | Yes | 6 | | Martin | 2006 | Spain | Europe | Primary early breast cancer | 818 | 43 | 59 | Pretreatment | I, II, III | 30 | DFS | N | N | Yes | 7 | | Molina | 1998 | Spain | Europe | Primary breast cancer | 413 | N | N | Pretreatment | I–IV | 35 | DFS | 5.0 | DFS | No | 5 | | Molina | 2010 | Spain | Europe | Primary breast cancer | 2062 | N | N | Pretreatment | I–IV | 30 | DFS, OS | 5 | DFS, OS | Yes | 8 | | Nakamura | 2017 | Japan | Asia | Primary breast cancer | 208 | 93.6 | 55.3 | Not clear | 0–IV | 27 | OS | 5 | OS | No | 7 | | Nan | 2017 | China | Asia | Primary breast cancer | 46 | 27 | 60 | Pretreatment | Not clear | N | N | 2.885 | OS | No | 5 | | Nieder | 2015 | Norway | Europe | Breast cancer with brain metastases | 14 | 13.8 | | Before recurrence | M | 77 | OS | N | N | No | 5 | | Nishimiya | 2014 | Japan | Asia | Primary breast cancer | 247 | 120 | 51.7 | Pretreatment | I, II, III | 28 | DFS, OS | 2.5 | DFS, OS | No | 8 | | Nisman | 2013 | Israel | Asia | Primary early breast cancer | 159 | 76 | N | Pretreatment | I, II, III | 30.0 | DFS | N | N | Yes | 6 | | Park | 2008 | Korea | Asia | Early-stage breast cancer | 740 | 37.2 | 47 | Pretreatment | I, II, III | 20.11 | DFS, OS | 3.88 | DFS, OS | Yes | 8 | | Pierga | 2012 | France | Europe | Metastatic breast cancers | 84 | 14.9 | 57 | After recurrence | M | N | N | N | PFS | No | 6 | | Rasmy | 2016 | Egypt | Africa | Early-stage breast cancer | 280 | 33.18 | 49 | Pretreatment | I, II, III | 25 | DFS, OS | N | N | Yes | 7 | | Richard | 1988 | USA | America | Stage II and III breast cancer | 529 | 72 | N | Pretreatment | II, III | N | N | 20 | DFS, OS | Yes | 8 | | Shao | 2015 | China | Asia | Early-stage breast cancer | 432 | N | 50 | Pretreatment | I, II, III | 25 | DFS, OS | 5.0 | DFS, OS | Yes | 8 | | Shering | 1998 | Ireland | Europe | Operable breast cancer | 368 | 39.36 | 56 | Pretreatment | I, II, III | 30 | DFS, OS | N | N | No | 7 | | Turanli | 2010 | Turkey | Europe | Isolated bone metastasis breast cancer | 129 | 38 | 51 | After bone metastasis | M | 30 | PFS, OS | N | N | Yes | 7 | | Uehara | 2008 | Japan | Asia | Primary breast cancer | 1663 | N | N | Pretreatment | I–IV | 28 | DFS, OS | 5.0 | DFS, OS | No | 7 | | Velaiutham | 2008 | Malaysia | Asia | Primary breast cancer | 322 | N | N | Pretreatment | I–IV | 50 | OS | N | N | No | 5 | | Wang | 2014 | China | Asia | Breast cancer | 86 | N | N | Not clear | Not clear | 25.00 | OS | 3.40 | OS | No | 5 | | Wu | 2014 | China | Asia | Early-stage breast cancer | 470 | 49.9 | 48 | Pretreatment | I, II, III | 25 | DFS, OS | 5.0 | DFS, OS | Yes | 7 | | Zhao | 2011 | China | Asia | Stage IV breast cancer with bone metastases | 60 | 31.4 | 48.5 | Pretreatment | M | 25 | PFS | 10 | PFS | No | 8 |
|
|
